MARKET

DBVT

DBVT

Dbv Technologies S A
NASDAQ
0.7491
-0.0176
-2.30%
Closed 16:00 03/28 EDT
OPEN
0.7321
PREV CLOSE
0.7667
HIGH
0.7600
LOW
0.7200
VOLUME
14.56K
TURNOVER
0
52 WEEK HIGH
2.370
52 WEEK LOW
0.6500
MARKET CAP
144.47M
P/E (TTM)
-1.9595
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at DBVT last week (0318-0322)?
Weekly Report · 4d ago
12 Health Care Stocks Moving In Monday's Pre-Market Session
Applied DNA Sciences (APDN) stock moved upwards by 33.1% to $0.49 during Monday's pre-market session. XTL Biopharmaceuticals (XTLB) shares increased by 19.31%. 2seventy bio (TSVT) shares rose 17.7%. Titan Pharma (TTNP) shares declined by 18.2% during the session.
Benzinga · 03/18 13:05
Weekly Report: what happened at DBVT last week (0311-0315)?
Weekly Report · 03/18 09:03
Weekly Report: what happened at DBVT last week (0304-0308)?
Weekly Report · 03/11 09:03
DBV Technologies Announces Completion of Annual Report
TipRanks · 03/08 21:24
Buy Rating Affirmed for DBV Technologies on Viaskin Patch Development and Positive Trial Outcomes
TipRanks · 03/08 11:29
DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document
Barchart · 03/08 08:33
EUROPE RESEARCH ROUNDUP-Aena SME SA, Arkema SA, ITV Plc
Analysts revise ratings and price targets on several European companies. Aena SME SA, Arkema SA, ITV Plc and ITV raise their targets. HSBC cuts target price to EUR 107 from EUR 111 for ITV. A.G. Barr raises to equal weight from underweight.
Reuters · 03/08 07:03
More
About DBVT
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.

Webull offers DBV Technologies SA - ADR stock information, including NASDAQ: DBVT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DBVT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DBVT stock methods without spending real money on the virtual paper trading platform.